Barings’s Nektar Therapeutics NKTR Stock Holding History

Barings’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-400	Closed	-$213K	–	697
2019 Q2	$213K	Buy	+400	New	+$201K	﹤0.01%	640

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barings's NKTR Position: Q3 2019 in Review

Barings sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 400 shares — an estimated $213K sold.

Barings first reported a position in NKTR in Q2 2019 and held it in 1 quarter. The position peaked at $213K in Q2 2019. 287 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

Barings reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
Barings sold 400 Nektar Therapeutics shares in Q3 2019, an estimated $213K.
Barings first reported a position in Nektar Therapeutics in Q2 2019 and held it in 1 quarter.
Barings's Nektar Therapeutics position peaked at $213K in Q2 2019.
287 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Barings's 13F filing for Q3 2019, filed 13 Nov 2019.